276.5: Targeted Tx

Question 1

Pertuzumab

Trastuzumab

Answer 1

Breast Cancer tx (Anti-Her2)

SE: Cardiotoxicity

Question 2

Gemtuzumab

Answer 2

AML tx (anti-CD33+calicheamicin)

SE: veno-occlusive disorder

Question 3

Bevacizumab

Answer 3

Numerous indications (anti-VEGF)
SE: impaired wound healing, hemorrhage

Question 4

Nivolumab

Pembrolizumab

Answer 4

Numerous Indications (anti-PD - immunotx)
SE: rash, diarrhea, liver tox (autoimmunity)

Question 5

Ipilimumab

Answer 5

Numerous indications (anti-CTLA-4 - immunotx)
SE: rash, diarrhea, liver tox (autoimmunity)

Question 6

Erlotinib

Gefitinib

Answer 6

Non-small cell lung cancer (TKIs at EGFR)

SE: rash, diarrhea, pneumonitis

Question 7

Sunitinib

Sorafenib

Answer 7

Renal Cell Carcinoma (TKIs at VEGF)

SE: HTN, rash, hair changes

Question 8

Alectinib

Answer 8

Non-Small cell lung cancer (TKIs at ALK)

SE: edema, liver toxicity, myalgia

Question 9

Imatinib

Dasatinib

Answer 9

CML and ALL (+Ph) (TKIs at BCR-ABL)

SE: neutropenia, edema, pleural effusion (only dasatinib)

Question 10

Ruxolitinib

Answer 10

Jak-2 inhibitor
tx MPN and GvHD
SE: infection, secondary skin cancer